John Colwell to Blood Platelets
This is a "connection" page, showing publications John Colwell has written about Blood Platelets.
Connection Strength
1.040
-
The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003 Jul; 26(7):2181-8.
Score: 0.192
-
Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care. 1995 Aug; 18(8):1150-5.
Score: 0.111
-
Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care. 1994 Aug; 17(8):818-23.
Score: 0.104
-
Antiplatelet agents and diabetic vascular disease. Trans Am Clin Climatol Assoc. 1987; 98:119-27.
Score: 0.061
-
Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care. 1986 Mar-Apr; 9(2):140-8.
Score: 0.058
-
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis. Haemostasis. 1986; 16(6):433-8.
Score: 0.057
-
Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes. 1985 Nov; 34(11):1127-33.
Score: 0.057
-
Do platelets have anything to do with diabetic microvascular disease? Diabetes. 1983 May; 32 Suppl 2:14-9.
Score: 0.048
-
Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am. 2001 Dec; 30(4):1011-30.
Score: 0.043
-
Increased platelet arachidonic acid metabolism in diabetes mellitus. Diabetes. 1981; 30(Suppl 2):44-8.
Score: 0.040
-
Platelet function in diabetes mellitus. Br J Haematol. 1980 Apr; 44(4):521-6.
Score: 0.038
-
Aspirin therapy in diabetes. Diabetes Care. 1997 Nov; 20(11):1767-71.
Score: 0.032
-
Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with an without vascular disease. Metabolism. 1977 Mar; 26(3):279-85.
Score: 0.031
-
Altered platelet function in diabetes mellitus. Diabetes. 1976; 25(2 SUPPL):826-31.
Score: 0.029
-
Antiplatelet drugs and prevention of macrovascular disease in diabetes mellitus. Metabolism. 1992 May; 41(5 Suppl 1):7-10.
Score: 0.022
-
Pathophysiology of vascular disease in diabetes: effects of gliclazide. Am J Med. 1991 Jun 24; 90(6A):50S-54S.
Score: 0.021
-
A review of the development of large-vessel disease in diabetes mellitus. Am J Med. 1988 Nov 28; 85(5A):113-8.
Score: 0.018
-
Insulin and arachidonic acid metabolism in diabetes mellitus. Metabolism. 1985 Dec; 34(12 Suppl 1):32-6.
Score: 0.014
-
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics. Horm Metab Res Suppl. 1985; 15:69-73.
Score: 0.013
-
New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am J Med. 1983 Nov 30; 75(5B):67-80.
Score: 0.012
-
Atherosclerosis in diabetes mellitus. J Chronic Dis. 1981; 34(1):1-4.
Score: 0.010
-
Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care. 1981 Jan-Feb; 4(1):121-33.
Score: 0.010
-
Platelet adhesion and aggregation in diabetes mellitus. Metabolism. 1979 Apr; 28(4 Suppl 1):394-400.
Score: 0.009
-
Inhibition of labile aggregation-stimulating substance (LASS) and platelet aggregation in diabetes mellitus. Diabetes. 1975 Jul; 24(7):684-7.
Score: 0.007
-
Disseminated intravascular coagulation in diabetes mellitus, with reference to the role of increased platelet aggregation. Diabetes. 1972 Feb; 21(2):108-13.
Score: 0.001